ND4 IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON WORKPLACE PRODUCTIVITY: RESULTS FROM TWO U.S. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIALS


A23Abstracts

ND4
IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON
WORKPLACE PRODUCTIVITY: RESULTS FROM TWO U.S.
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
MULTICENTER TRIALS
Gagne JJ1, Lofland JH1, Rupnow M2, Smith KD1, Poston S1, Pizzi LT1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Ortho-McNeil
Janssen Scientific Affairs, LLC, Titusville, NJ, USA
OBJECTIVE: To compare the impact of topiramate 100 mg/day
versus placebo on workplace productivity among individuals
with migraine, using data from two six-month randomized,
double-blind trials. METHODS: A five-item survey for each
migraine attack captured the participants’ number of hours
absent from work (“absenteeism”, A), number of hours worked
with migraine (WM), and degree of effectiveness (E) while
working with migraine. Presenteeism (P) was calculated as the
product of WM and E. Total lost productivity was the sum of A
and P. The mean monthly (28-day) rate of lost productivity per
person at baseline and double-blind periods was compared
between the study arms using Wilcoxon rank sum tests.
RESULTS: A total of 449 subjects were enrolled in the trials (226

topiramate, 223 placebo). Of these, 325 subjects reported any
lost productivity at baseline (162 topiramate, 163 placebo).
Mean ± SD age was 40 ± 11 years, 88.6% were female, and
91.1% were Caucasian. Demographic characteristics were
similar between groups. The most common adverse events for
topiramate in the clinical trials included paresthesia, nausea,
anorexia, and fatigue. At baseline, the mean rates of total lost
productivity were 10.4 hours/28 days for topiramate 100 mg/d
and 10.1 hours/28 days for placebo (not significant). Total lost
productivity hours/28 days for topiramate 100 mg/d versus
placebo were 5.2 versus 6.3 in month 1, and 3.4 versus 4.8, 2.9
versus 4.4, 3.0 versus 4.4, 2.8 versus 4.7, and 2.8 versus 3.1 over
the next five months. Improvements in productivity associated
with topiramate 100 mg/d in comparison with placebo were sta-
tistically significant (p < 0.05) in months 1, 2, 3, 4, and 5. CON-
CLUSIONS: This is one of the first studies examining the impact
of topiramate on workplace productivity, based on post-hoc
analysis of randomized trials. Our findings suggest that topira-
mate 100 mg/day may be associated with improvements in pro-
ductivity among individuals with migraine.